-
Something wrong with this record ?
Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry
Z Motovska, Z Sujanova, S Wimmerova, J Ardo, M Skrakova, P Widimsky
Language English Country United States
Document type Comparative Study, Controlled Clinical Trial
NLK
ScienceDirect (archiv)
from 2006-01-01 to 2009-12-31
- MeSH
- Adenosine Diphosphate pharmacology MeSH
- Aspirin therapeutic use MeSH
- Platelet Activating Factor drug effects MeSH
- Financing, Organized MeSH
- Platelet Aggregation Inhibitors therapeutic use MeSH
- Cardiovascular Diseases drug therapy blood prevention & control MeSH
- Cations pharmacology MeSH
- Drug Resistance MeSH
- Middle Aged MeSH
- Humans MeSH
- Propyl Gallate pharmacology MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Case-Control Studies MeSH
- In Vitro Techniques MeSH
- Platelet Glycoprotein GPIIb-IIIa Complex metabolism MeSH
- Platelet Function Tests methods standards instrumentation MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Controlled Clinical Trial MeSH
- Comparative Study MeSH
To compare the newer inductor of platelet aggregation cationic propyl gallate (CPG) with adenosine diphosphate (ADP) for the examination of aspirin (ASA) effectivity with optical aggregometry. In total,116 patients were prospectively enrolled with a stable cardiovascular disease, taking ASA 100 mg/day for >or=1 month. The control group consisted of 62 healthy volunteers. A platelet aggregation was investigated by optical aggregometry (aggregometer LASER 4x; BIO ART, Sint-Katelijne-Waver, Belgium). CPG and ADP were added as aggregating agents. The measured parameters were CPG-slope (%/min) and ADP max (%). Using the CPG-slope values from the control group, the CPG-slope cut-off value was determined to define a laboratory ASA-noneffectively treated patient. The values from control group followed a normal distribution (Shapiro-Wilk test). We calculated the cut-off value using the 1-tailed 95% confidence interval. The CPG-slope cut-off value was 79 %/min for an ASA-effectively treated patient. We marked the patients as laboratory ASA-noneffective treated when the CPG-slope was >79%/min. In the same way we defined the cut-off value for ADP-max. We identified the aspirin treatment as ineffective when the value of ADP-max was >62%. The values of CPG-slope and ADP-max were in close correlation in the group of patients treated with aspirin with a highly significant correlation index (r=0.671, P<0.001). By CPG-induced optical aggregation, 33,6% were ASA-noneffectively treated patients. When using both inductors, the proportion of ASA-noneffectively treated patients was 25%. Using both tests, 72.4% of patients were equally divided. ASA-noneffectively treated patients were commonly more obese (46.2%), had hypertension (94.9%) and hypercholesterolemia (73.7%), and were less commonly treated with statins (30.8%) than the aspirin effectively treated patients (42%, 88.2%, 59.2%, and 42.1%, respectively). The detected differences were not statistically significant. Cationic propyl gallate is an optimal inductor for optical aggregometry to monitor laboratory effectiveness of aspirin therapy in routine clinical pratice. The determined high prevalence of laboratory aspirin ineffectiveness highlights the clinical importance of the problem. This study brings attention to the importance of controlling cardiovascular risk factors.
- 000
- 04604naa 2200517 a 4500
- 001
- bmc10013268
- 003
- CZ-PrNML
- 005
- 20140221150417.0
- 008
- 100602s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Moťovská, Zuzana $7 xx0104795
- 245 10
- $a Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry / $c Z Motovska, Z Sujanova, S Wimmerova, J Ardo, M Skrakova, P Widimsky
- 314 __
- $a Cardiocentre, Third Medical School Charles University, Prague, Czech Republic, and the Clinic of Haematologie, University Hospital, Bratislava, Slovak Republic. zuzana.motovska@iex.cz
- 520 9_
- $a To compare the newer inductor of platelet aggregation cationic propyl gallate (CPG) with adenosine diphosphate (ADP) for the examination of aspirin (ASA) effectivity with optical aggregometry. In total,116 patients were prospectively enrolled with a stable cardiovascular disease, taking ASA 100 mg/day for >or=1 month. The control group consisted of 62 healthy volunteers. A platelet aggregation was investigated by optical aggregometry (aggregometer LASER 4x; BIO ART, Sint-Katelijne-Waver, Belgium). CPG and ADP were added as aggregating agents. The measured parameters were CPG-slope (%/min) and ADP max (%). Using the CPG-slope values from the control group, the CPG-slope cut-off value was determined to define a laboratory ASA-noneffectively treated patient. The values from control group followed a normal distribution (Shapiro-Wilk test). We calculated the cut-off value using the 1-tailed 95% confidence interval. The CPG-slope cut-off value was 79 %/min for an ASA-effectively treated patient. We marked the patients as laboratory ASA-noneffective treated when the CPG-slope was >79%/min. In the same way we defined the cut-off value for ADP-max. We identified the aspirin treatment as ineffective when the value of ADP-max was >62%. The values of CPG-slope and ADP-max were in close correlation in the group of patients treated with aspirin with a highly significant correlation index (r=0.671, P<0.001). By CPG-induced optical aggregation, 33,6% were ASA-noneffectively treated patients. When using both inductors, the proportion of ASA-noneffectively treated patients was 25%. Using both tests, 72.4% of patients were equally divided. ASA-noneffectively treated patients were commonly more obese (46.2%), had hypertension (94.9%) and hypercholesterolemia (73.7%), and were less commonly treated with statins (30.8%) than the aspirin effectively treated patients (42%, 88.2%, 59.2%, and 42.1%, respectively). The detected differences were not statistically significant. Cationic propyl gallate is an optimal inductor for optical aggregometry to monitor laboratory effectiveness of aspirin therapy in routine clinical pratice. The determined high prevalence of laboratory aspirin ineffectiveness highlights the clinical importance of the problem. This study brings attention to the importance of controlling cardiovascular risk factors.
- 650 _2
- $a adenosindifosfát $x farmakologie $7 D000244
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a Aspirin $x terapeutické užití $7 D001241
- 650 _2
- $a kardiovaskulární nemoci $x farmakoterapie $x krev $x prevence a kontrola $7 D002318
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a kationty $x farmakologie $7 D002412
- 650 _2
- $a léková rezistence $7 D004351
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a faktor aktivující destičky $x účinky léků $7 D010972
- 650 _2
- $a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
- 650 _2
- $a vyšetření funkce trombocytů $x metody $x normy $x přístrojové vybavení $7 D010979
- 650 _2
- $a trombocytový glykoproteinový komplex IIb-IIIa $x metabolismus $7 D019039
- 650 _2
- $a propylgalan $x farmakologie $7 D011435
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a techniky in vitro $7 D066298
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a klinické zkoušky kontrolované $7 D018848
- 700 1_
- $a Šujanová, Zdenka. $7 xx0248979
- 700 1#
- $a Wimmerová, Soňa $7 xx0234999
- 700 1_
- $a Ardó, Ján. $7 _AN058246
- 700 1_
- $a Skraková, Marcela, $d 1954- $7 xx0137989
- 700 1_
- $a Widimský, Petr, $d 1954- $7 jn20000402682
- 773 0_
- $t Translational Research: The Journal Of Laboratory & Clinical Medicine $w MED00152122 $g Roč. 150, č. 4 (2007), s. 246-252 $x 1931-5244
- 910 __
- $a ABA008 $b x $y 7 $z 0
- 990 __
- $a 20110222134556 $b ABA008
- 991 __
- $a 20140221151226 $b ABA008
- 999 __
- $a ok $b bmc $g 749135 $s 612763
- BAS __
- $a 3
- BMC __
- $a 2007 $b 150 $c 4 $d 246-252 $i 1931-5244 $m Translational research $n Transl Res $x MED00152122
- LZP __
- $a 2010-B2/ipme